LinkedIn · Nov 2025
The company said the award will help accelerate its first bi-directional chip for reading and writing brain activity.
High-precision, closed-loop neuromodulation devices
Company research
Public company, workplace, funding, and market signals
Overview
Torpedo Therapeutics is an early-stage neurotechnology/medical-device company building high-precision, closed-loop deep brain stimulation (DBS) systems for neurological disorders. Public sources describe an implantable micro-/nano-fabricated electrode platform, continuous neural sensing, automated stimulation adjustment, and machine-learning-based data analysis. The company was founded in 2018, is based in Cambridge with a Boston office, and appears to operate as a very small private team.
Primary product
High-precision, closed-loop deep brain stimulation (DBS) devices and associated neural-data/control platform
Founded
2018
Headquarters
85 Bolton St, Cambridge, MA 02140, United States
Team size
1-10 employees
Industry
Medical technology
Sub-industry
Closed-loop neuromodulation / deep brain stimulation devices
Offices
85 Bolton St, Cambridge, MA 02140, United States
BU Innovation Center, 8 Saint Mary's Street, Boston, MA 02215, United States
Business model
medical device development
software-enabled neural data analysis platform
Funding
Stage
Seed
Total raised
$5.6M
Latest round
Debt Financing · Dec 2024
Latest amount
$5M
People & investors
Investors
Work & culture
Product & market
Differentiators
- —Micro-electrodes claimed to be 150x smaller than existing commercial DBS electrodes
- —Single-neuron-level stimulation precision
- —Closed-loop sensing that automatically adjusts stimulation parameters
- —Machine-learning-driven neural data analysis and predictive control
- —A chip-based readout/control approach intended to replace bulky implantable pulse generators
Technology
micro-/nano-fabrication
micro-electrodes
closed-loop sensing and stimulation
machine learning
electronic chip readout and stimulation control
Scale & contact
Estimated revenue
~$1M estimated ARR
Latest news
NEMC / MassTech · Nov 2025
The NEMC Hub announced PROPEL awards, including $187,116 to Torpedo Therapeutics for developing miniaturized implantable brain-computer interfaces with single-neuron precision.
LinkedIn · Mar 2025
Founder and CEO Ingrid van Welie announced the company’s first USPTO patent related to micro-electrodes and adaptive closed-loop DBS stimulation control.
LinkedIn · Oct 2024
Ingrid van Welie announced the company joined NYU Stern’s Endless Frontier Labs cohort, a mentorship program for science/tech startups.
LinkedIn · Mar 2024
Rebrand announcement from Neural Dynamics Technologies Inc. to Torpedo Therapeutics Inc.; the post says the new name reflects the company’s high-precision, closed-loop implantable neuromodulation focus.
Jobs and careers at Torpedo Therapeutics
0 jobs at Torpedo Therapeutics
No open positions
Check back later for new openings